TFF Pharmaceuticals (NASDAQ:TFFP) Earns Buy Rating from Maxim Group

Share on StockTwits

Maxim Group reaffirmed their buy rating on shares of TFF Pharmaceuticals (NASDAQ:TFFP) in a research note issued to investors on Thursday morning, AnalystRatings.com reports. The brokerage currently has a $12.00 target price on the stock.

Several other analysts have also recently commented on TFFP. Zacks Investment Research cut TFF Pharmaceuticals from a buy rating to a hold rating in a report on Tuesday, May 26th. ValuEngine upgraded shares of TFF Pharmaceuticals from a hold rating to a buy rating in a research report on Thursday, April 2nd.

Shares of TFF Pharmaceuticals stock opened at $9.09 on Thursday. The firm has a fifty day moving average price of $6.24 and a two-hundred day moving average price of $5.17. TFF Pharmaceuticals has a fifty-two week low of $3.44 and a fifty-two week high of $10.25. The company has a market cap of $169.73 million and a PE ratio of -1.71.

TFF Pharmaceuticals (NASDAQ:TFFP) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.04. As a group, analysts forecast that TFF Pharmaceuticals will post -0.83 earnings per share for the current year.

In other TFF Pharmaceuticals news, Director Aaron G.L. Fletcher bought 20,000 shares of TFF Pharmaceuticals stock in a transaction dated Tuesday, May 26th. The stock was bought at an average cost of $5.08 per share, for a total transaction of $101,600.00. Following the purchase, the director now owns 95,000 shares of the company’s stock, valued at approximately $482,600. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

A number of institutional investors have recently added to or reduced their stakes in TFFP. Goldman Sachs Group Inc. bought a new position in TFF Pharmaceuticals in the fourth quarter valued at approximately $85,000. BlackRock Inc. boosted its stake in TFF Pharmaceuticals by 77.8% in the first quarter. BlackRock Inc. now owns 22,134 shares of the company’s stock valued at $84,000 after buying an additional 9,682 shares in the last quarter. Finally, Sigma Planning Corp grew its position in TFF Pharmaceuticals by 752.9% in the first quarter. Sigma Planning Corp now owns 89,550 shares of the company’s stock valued at $344,000 after acquiring an additional 79,050 shares during the last quarter. 5.68% of the stock is currently owned by hedge funds and other institutional investors.

TFF Pharmaceuticals Company Profile

TFF Pharmaceuticals, Inc, an early-stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing, or TFF, technology platform. It intends to initially focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.

Featured Story: S&P 500 Index

Receive News & Ratings for TFF Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TFF Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.